Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Jury Finds Novartis Guilty of Discrimination

By Drug Discovery Trends Editor | May 18, 2010

NEW YORK (AP) – A jury decided that the drug company Novartis engaged in a pattern of discrimination against women, paying them less than men, cheating them of promotions and treating pregnant women unfavorably.

The verdict returned in U.S. District Court in Manhattan also awarded $3.3 million in compensatory damages to a dozen women who, during a six-week trial, described the abuse they endured as they sold products for Novartis Pharmaceuticals Corp. The individual awards ranged from $50,000 to nearly $600,000, depending on each employee’s length of service and income.

The nine jurors also agreed that the company must pay punitive damages, though the jury must resume deliberations to fix the amount after hearing closing arguments on the subject Tuesday.

The case went to trial after a lawsuit alleged that Novartis had disrespected its female workers since 2002. It said it paid them less than men, promoted few of them and allowed a hostile workplace dominated by an old boys’ network to flourish.

In a statement, Novartis said it was disappointed by the verdict and would appeal.

“We believe the plaintiffs’ claims were unfounded,” it said.

The company said it had, during the time spanned by the lawsuit, implemented policies that set the highest standards for diversity and inclusion for its employees.

“We are proud of the public honor and recognition we have received for the policies and programs we have in place to support the advancement of women in the sales force,” the company said.

Lawyers for the plaintiffs praised the verdict, saying it would bring relief to the class of 5,600 Novartis female sales representatives.

“This verdict is the first step in bringing about long overdue changes at Novartis and other companies that encourage or tolerate unfair treatment of women in their workplaces,” attorney David Sanford said.

Another lawyer, Kate Kimpel, said: “This jury learned that Novartis is not somewhere you would want your wife, your mother, your sister or your daughter to work.”

She said the company had a corporate culture that expected female representatives to be available and amenable to sexual advances from the doctors they called on.

“Time and time again, Novartis looked the other way when female representatives complained about inappropriate doctors. And then, to add insult to injury, Novartis paid those same women less, wouldn’t promote them into management and punished them if they got pregnant,” Kimpel said.

Testimony at trial included the depiction of one district manager as so abusive of his power that he showed women pornographic images and invited them to sit on his lap.

During opening statements, Novartis attorney Richard Schnadig said the company might have been slow to investigate the claims against the manager, who was fired two years after the lawsuit was filed in 2004.

“He wasn’t that bad a manager. He was just terrible with women,” Schnadig told jurors.

Date: May 17, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Bayer’s Lynkuet approved by FDA for menopausal hot flashes
How stereo-correct data can de-risk AI-driven drug discovery
eConsent as the digital foundation for modern clinical trials 
Female Patient Being Reassured By Doctor In Hospital Room
Q&A: Thermo Fisher’s Luke Wilson on hitting 100% dose delivery with patient-centric supply
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE